Login / Signup

New drugs in cystic fibrosis: what has changed in the last decade?

Juliana RodaCatarina Pinto-SilvaIris A I SilvaCarla MaiaSusana AlmeidaRicardo FerreiraGuiomar Oliveira
Published in: Therapeutic advances in chronic disease (2022)
Cystic fibrosis (CF), a life-limiting chronic disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene, affects more than 90,000 people worldwide. Until recently, the only available treatments were directed to symptom control, but they failed to change the course of the disease. New drugs developed in the last decade have the potential to change the expression, function, and stability of CFTR protein, targeting the basic molecular defect. The authors seek to provide an update on the new drugs, with a special focus on the most promising clinical trials that have been carried out to date. These newly approved drugs that target specific CFTR mutations are mainly divided into two main groups of CFTR modulators: potentiators and correctors. New therapies have opened the door for potentially disease-modifying, personalized treatments for patients with CF.
Keyphrases